CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.85
−4.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.33
From 52W high−21.09%
Volume2.99M
Market cap$830.23M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$11.33
From 52W high
−21.09%
Volume
2.99M
Market cap
$830.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
−4.32%
YTD Return
+91.15%
SummaryUpdated Jun 1, 2026
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Needham, Massachusetts. Originally incorporated as Advantagene, Inc., the company rebranded to Candel Therapeutics in November 2020 before going public in July 2021. The company focuses on developing innovative immunotherapies designed to treat various forms of cancer by harnessing the body's immune system to fight tumors.
Similar companies
Latest newsMore news →